Homology models and molecular modeling of human retinoic acid metabolizing enzymes cytochrome P450 26A1 (CYP26A1) and P450 26B1 (CYP26B1)

Journal of Chemical Theory and Computation

Volumn 4, Issue 6, 2008, Pages 1021-1027

  Karlsson, Magnus ^a   Strid, Åke ^a   Sirsjö, Allan ^a   Eriksson, Leif A ^a  

^a ÖREBRO UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58149121148     PISSN: 15499618     EISSN: None     Source Type: Journal    
DOI: 10.1021/ct800033x     Document Type: Article

References (30)

1. Russell, R. M.; Ross, A. C.; Trumbo, P. R.; West, K. P. Retinol equivalency ratio of beta-carotene. J. Nutr. 2003, 133, 2915-2916.
2. Estey, E. H.; Giles, F. J.; Kantarjian, H.; O'Brien, S.; Cortes, J.; Freireich, E. J.; Lopez-Berestein, G.; Keating, M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocyte leukemia. Blood 1999, 94, 2230-2235.
3. Ahmad, N.; Mukhtar, H. Cytochrome P450: A target for drug development for skin diseases. J. Invest. Dermatol. 2004, 123, 417-425.
4. Miano, J. M.; Kelly, L. A.; Artacho, C. A.; Nuckolls, T. A.; Piantedosi, R.; Blaner, W. S. all-trans-retinoic acid reduces neointimal formation and promotes favorable geometric remodeling of the rat carotid artery after balloon withdrawal injury. Circulation 1998, 98, 1219-1227.
5. Gidlof, A. C.; Ocaya, P.; Krivospitskaya, O.; Sirsjo, A. Vitamin A: a drug for prevention of restenosis/reocclusion after percutaneous coronary intervention. Clin. Sci. 2008, 114, 19-25.
6. Gidlof, A. C.; Romert, A.; Olsson, A.; Torma, H.; Eriksson, U.; Sirsjo, A. Increased retinoid signaling in vascular smooth muscle cells by proinflammatory cytokines. Biochem. Biophys. Res. Commun. 2001, 286, 336-342.
7. Muindi, J.; Frankel, S. R.; Miller, W. H.; Jakubowski, A.; Scheinberg, D. A.; Young, C. W.; Dmitrovsky, E.; Warrell, R. P. Continuous Treatment with All-Trans Retinoic Acid Causes a Progressive Reduction in Plasma Drug Concentrations - Implications for Relapse and Retinoid Resistance in Patients with Acute Promyelocytic Leukemia. Blood 1992, 79, 299-303.
8. Napoli, J. L. Retinoic acid biosynthesis and metabolism. Faseb J. 1996, 10, 993-1001.
9. McSorley, L. C.; Daly, A. K. Identification of human cytochrome P450 isoforms that contribute to all-trans-Retinoic Acid 4-hydroxylation. Biochem. Pharmacol. 2000, 60, 517-526.
10. White, J. A.; Becket Jones, B.; Guo, Y. D.; Dilworth, F. J.; Bonasoro, J.; Jones, G.; Petkovich, M. cDNA cloning of human retinoic acid-metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450 (CYP26). J. Biol. Chem. 1997, 272, 18538-18541.
11. Taimi, M.; Helvig, C.; Wisniewski, J.; Ramshaw, H.; White, J.; Amad, M.; Korczak, B.; Petkovich, M. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J. Biol. Chem. 2004, 279, 77-85.
12. Ocaya, P.; Gidlof, A. C.; Olofsson, P. S.; Torma, H.; Sirsjo, A. CYP26 inhibitor R115866 increases retinoid signaling in intimai smooth muscle cells. Arterioscler., Thromb., Vasc. Biol. 2007, 27, 1542-1548.
13. Loudig, O.; MacLean, G. A.; Dore, N. L.; Luu, L.; Petkovich, M. Transcriptional co-operativity between distant retinoic acid response elements in regulation of Cyp26A1 inducibility. Biochem. J. 2005, 392, 241-248.
14. Vanwauwe, J. P.; Coene, M. C.; Goossens, J.; Vannijen, G.; Cools, W.; Lauwers, W. Ketoconazole Inhibits the Invitro and Invivo Metabolism of All-Trans-Retinoic Acid. J. Pharmacol. Exp. Ther. 1988, 245, 718-722.
15. Acevedo, P.; Bertram, J. S. Liarozole Potentiates the Cancer Chemopreventive Activity of and the up-Regulation of Gap Junctional Communication and Connexin43 Expression by Retinoic Acid and Beta-Carotene in 10t1/2 Cells. Carcinogenesis 1995, 16, 2215-2222.
16. Njar, V. C. O.; Gediya, L.; Purushottamachar, P.; Chopra, P.; Vasaitis, T. S.; Khandelwal, A.; Mehta, J.; Huynh, C.; Belosay, A.; Patel, J. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg. Med. Chem. 2006, 14, 4323-4340.
17. Van Heusden, J.; Van Ginckel, R.; Bruwiere, H.; Moelans, P.; Janssen, B.; Floren, W.; van der Leede, B. J.; van Dun, J.; Sanz, G.; Venet, M.; Dillen, L.; Van Hove, C.; Willemsens, G.; Janicot, M.; Wouters, W. Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity. Br. J. Cancer 2002, 86, 605-611.
18. Stoppie, P.; Borgers, M.; Borghgraef, P.; Dillen, L.; Goossens, J.; Sanz, G.; Szel, H.; Van Hove, C.; Van Nyen, G.; Nobels, G.; Vanden Bossche, H.; Venet, M.; Willemsens, G.; Van Wauwe, J. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J. Pharmacol. Exp. Ther. 2000, 293, 304-312.
19. Patel, J. B.; Huynh, C. K.; Handratta, V. D.; Gediya, L. K.; Brodie, A. M. H.; Goloubeva, O. G.; Clement, O. O.; Nanne, N. P.; Soprano, D. R.; Njar, V. C. O. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J. Med. Chem. 2004, 47, 6716-6729.
20. Vasudevan, J.; Johnson, A. T.; Huang, D.; Chandrartna, R. A. U.S. Patent 6.252.090, 2005.
21. Mulvihill, M. J.; Kan, J. L. C.; Cooke, A.; Bhagwat, S.; Beck, P.; Bittner, M.; Cesario, C.; Keane, D.; Lazarescu, V.; Nigro, A.; Nillson, C.; Panicker, B.; Smith, V.; Srebernak, M.; Sun, F. L.; O'Connor, M.; Russo, S.; Fischetti, G.; Vrkljan, M.; Winski, S.; Castelhano, A. L.; Emerson, D.; Gibson, N. W. 3-[6-(2-dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dim ethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent. Bioorg. Med. Chem. Lett. 2006, 16, 2729-2733.
22. Yee, S. W.; Jarno, L.; Gomaa, M. S.; Elford, C.; Ooi, L. L.; Coogan, M. P.; McClelland, R.; Nicholson, R. I.; Evans, B. A. J.; Brancale, A.; Simons, C. Novel tetralone-derived retinoic acid metabolism blocking agents: Synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays. J. Med. Chem. 2005, 48, 7123-7131.
23. Gomaa, M. S.; Yee, S. W.; Milbourne, C. E.; Barbera, M. C.; Simons, C.; Brancale, A. Homology model of human retinoic acid metabolising enzyme cytochrome P450 26A1 (CYP26A1): Active site architecture and ligand binding. J. Enzyme Inhib. Med. Chem. 2006, 21, 361-369.
24. Molecular Operating Environment, version 2005.06; Chemical Computing Group: Montreal, QC, 2005.
25. Molecular Operating Environment,version 2006.08; Chemical Computing Group: Montreal, QC, 2006.
26. Ponder, J. W.; Case, D. A. Force fields for protein simulations. Adv. Protein Chem. 2003, 66, 27-85.
27. 2
28. Edelsbrunner, H. Weighted Alpha Shapes; technical paper of the Department of Computer Science; University of Illinois: Champaign, IL
29. Aqvist, J.; Medina, C.; Samuelsson, J. E. New Method for Predicting Binding-Affinity in Computer-Aided Drug Design. Protein Eng. 1994, 7, 385-391.
30. RAMPAGE server: http://mordred.bioc.cam.ac.uk/~rapper/rampage.php (accessed Dec 12, 2007).